Literature DB >> 16799706

E-cadherin expression in transitional cell carcinomas.

Eszter Székely1, Virág Török, Tamás Székely, Péter Riesz, Imre Romics.   

Abstract

The authors analyzed the expression of E-cadherin, one of the most important cell adhesion molecules, on histological slides of tumors of bladder cancer patients. The aim of the study was to see whether there is any association between E-cadherin expression and tumor grade, stage, age and gender of the patients, number of recurrences, or overall survival. The samples were examined in 51 primary bladder transitional cell carcinomas (TCC) of 50 patients, resected by transurethral resection (TUR) between January 1, 1996 and January 1, 1997. Immunoreactions were performed with monoclonal anti-human E-cadherin antibody. Forty of the fifty patients could be clinically followed. The analysis of the results on these forty patients was performed by contingency analysis and significance was assessed by chi2 test. No significant association between E-cadherin expression and tumor grade, stage, age or gender of the patients, the number of recurrences, or overall survival could be seen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799706     DOI: 10.1007/bf02893447

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  25 in total

1.  Epithelial-type and neural-type cadherin expression in malignant noncarcinomatous neoplasms with epithelioid features that involve the soft tissues.

Authors:  William B Laskin; Markku Miettinen
Journal:  Arch Pathol Lab Med       Date:  2002-04       Impact factor: 5.534

2.  Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.

Authors:  Yohei Horikawa; Kokichi Sugano; Masanori Shigyo; Hidenobu Yamamoto; Masaaki Nakazono; Hiroyuki Fujimoto; Yae Kanai; Setsuo Hirohashi; Tadao Kakizoe; Tomonori Habuchi; Tetsuro Kato
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

3.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

4.  Genetic and biochemical dissection of protein linkages in the cadherin-catenin complex.

Authors:  T S Jou; D B Stewart; J Stappert; W J Nelson; J A Marrs
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

Review 5.  Current management of invasive and metastatic transitional cell carcinoma of the bladder.

Authors:  J B Thrasher; E D Crawford
Journal:  J Urol       Date:  1993-05       Impact factor: 7.450

6.  Changes in cadherin-catenin complexes in the progression of human bladder carcinoma.

Authors:  L A Giroldi; P P Bringuier; T Shimazui; K Jansen; J A Schalken
Journal:  Int J Cancer       Date:  1999-07-02       Impact factor: 7.396

Review 7.  Connecting estrogen receptor function, transcriptional repression, and E-cadherin expression in breast cancer.

Authors:  Eric R Fearon
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

8.  Reduced E-cadherin and alpha-catenin expressions have no prognostic role in bladder carcinoma.

Authors:  Ismail Turker Koksal; Mutlu Ates; Ahmet Danisman; Cem Sezer; Akif Ciftcioglu; Gulten Karpuzoglu; Metin Sevuk
Journal:  Pathol Oncol Res       Date:  2006-03-23       Impact factor: 3.201

9.  E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder.

Authors:  J S Ross; A D del Rosario; H L Figge; C Sheehan; H A Fisher; H X Bui
Journal:  Hum Pathol       Date:  1995-09       Impact factor: 3.466

Review 10.  Cadherins in cancer: implications for invasion and metastasis.

Authors:  M Takeichi
Journal:  Curr Opin Cell Biol       Date:  1993-10       Impact factor: 8.382

View more
  1 in total

1.  [Use of silicon chip technology to detect protein-based tumor markers in bladder cancer].

Authors:  T Jäger; T Szarvas; F vom Dorp; C Börgermann; M Schenck; K W Schmid; H Rübben
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.